A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin

Intravenous immunoglobulins (IVIGs) were initially designed to treat patients with primary immunodeficiencies (PID). Due to the multidirectional effect of IVIGs on the immune system, a range of nosological entities, in which these agents are successfully administered, is steadily expanding. As of no...

Celý popis

Podrobná bibliografie

Hlavní autoři:	T V Latysheva, E A Latysheva, I A Martynova
Médium:	Artigo
Jazyk:	Russo
Vydáno:	"Consilium Medicum" Publishing house 2016-04-01
Edice:	Терапевтический архив
Témata:	primary immunodeficiency replacement immunotherapy intravenous immunoglobulins immunomodulatory therapy
On-line přístup:	https://ter-arkhiv.ru/0040-3660/article/viewFile/31987/pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!